Title
Category
Credits
Event date
Cost
  • CMHC
  • 1.50 ACPE Pharmacy
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 ANCC
  • 1.50 CDE
  • 1.50 Participation
$0.00
Residual ASCVD risk may be present even after the optimization of LDL-C levels and increasing evidence has suggested that elevated Lp(a) is an emerging CVD risk factor that has been shown to be a causal CVD risk factor in epidemiological and genetic studies, as well as enhance CVD risk prediction in certain patients. As emerging CVD risk factors, including Lp(a), are increasingly recognized as a target for therapy in the prevention and treatment of ASCVD, clinicians should be aware of the therapeutic advances in this field. 
  • CMHC
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Effectively managing high cholesterol level and safely lowering LDL-C is crucial for preventing and reducing the risk of adverse cardiovascular events. However, achieving LDL-C goals remains suboptimal, particularly in high-risk and very high-risk patients. The landscape of lipid lowering therapy has significantly evolved, with new consensus statements, newer agents, and important evidence that may help address some current gaps.
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit
  • 0.50 ANCC
  • 0.50 CDE
  • 0.50 Participation
$0.00
This Ace the Case Series is designed to be quick and offer high-level takeaways and pearls.Case #1:  A 37-Year-Old Man with Incidental Hepatic Steatosis on Abdominal UltrasoundDuring this Ace the Case activity, you will learn about risk factors for metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), and advanced fibrosis, as well as the current and emerging noninvasive liver assessment tests.
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit
  • 0.50 ANCC
  • 0.50 Participation
$0.00
This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA.  The session, "The Burden of Resistant Hypertension in Women: Novel and Emerging Approaches to Improve Outcomes" was presented by Debbie Cohen, MDDr. Cohen discussed:
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
$0.00
This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA.  The symposium, "The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes" was presented by Pam R. Taub, MD, Erin D. Michos, MD, and Jennifer Green, MD. 
  • CMHC
  • 2.25 ACPE Pharmacy
  • 2.25 AMA PRA Category 1 Credit
  • 2.25 ANCC
  • 2.25 Participation
$0.00
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), including in the development of hypertension and risk of adverse cardiovascular outcomes. Additionally, the impact of commonly-used medications with high sodium content contributes to this burden. As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including patients with insufficient or impaired sleep, as well as practical strategies to minimize the impact of elevated sodium.
  • CMHC
  • 0.50 ACPE Pharmacy
  • 0.50 AMA PRA Category 1 Credit
  • 0.50 ANCC
  • 0.50 Participation
$0.00
CardioNerds Cofounder Dr. Amit Goyal, Chair of the CardioNerds Heart Failure Committee Dr. Jenna Skowronski, and Episode FIT Lead Dr. Shazli Khan discuss iron deficiency and its impact on heart failure with Dr. Robert Mentz, Chief of Heart Failure at Duke University and principal investigator of the HEART-FID trial. In this case-based discussion, they cover the diagnostic criteria of iron deficiency in heart failure, epidemiology, and strengths and limitations of different iron formulations.
  • CMHC
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.25 ANCC
  • 1.25 Participation
$0.00
Welcome to our micro-module webcast on the challenges of managing chronic kidney disease (CKD) and diabetes. After diagnosis, slowing CKD progression in type 2 diabetes (T2D) continues to pose a major challenge. Although new therapies, such as sodium-glucose cotransporter-2 (SGLT-2) inhibitors, have emerged, residual morbidity and mortality persist. Additional strategies are required to slow kidney disease progression, especially targeting inflammation and fibrosis.

Pages